Market revenue in 2023 | USD 4,224.4 million |
Market revenue in 2030 | USD 6,354.5 million |
Growth rate | 6% (CAGR from 2023 to 2030) |
Largest segment | Attenuated vaccine |
Fastest growing segment | DNA Vaccines |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Attenuated Vaccine, Inactivated Vaccine, Subunit Vaccines, Toxoid Vaccines, DNA Vaccines |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to vaccine contract manufacturing market will help companies and investors design strategic landscapes.
attenuated vaccine was the largest segment with a revenue share of 29.94% in 2023. Horizon Databook has segmented the Global vaccine contract manufacturing market based on attenuated vaccine, inactivated vaccine, subunit vaccines, toxoid vaccines, dna vaccines covering the revenue growth of each sub-segment from 2018 to 2030.
Horizon Databook provides a detailed overview of global-level data and insights on the Global vaccine contract manufacturing market , including forecasts for subscribers. This global databook contains high-level insights into Global vaccine contract manufacturing market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account